Skip to main content

A comparison of the efficacy and safety of iopamidol-370 and iodixanol-320 in patients undergoing multidetector-row computed tomography.

Publication ,  Journal Article
Sahani, DV; Soulez, G; Chen, K-M; Lepanto, L; Xu, J-R; Nelson, RC; Grazioli, L; Vanzulli, A; Heiken, JP; Investigators of the IMPACT Study,
Published in: Invest Radiol
December 2007

OBJECTIVES: To prospectively compare the effects on heart rate (HR) and contrast enhancement efficacy of iopamidol-370 and iodixanol-320 in contrast-enhanced, multidetector-row computed tomography (CE-MDCT). METHODS: IMPACT is a multicenter, double-blind study involving 166 patients undergoing CE-MDCT of the liver (n = 121) or peripheral arteries (n = 45) randomized to receive equi-iodine doses (40 gI) of iopamidol-370 or iodixanol-320 intravenous at 4 mL/s. CE-MDCT was performed using 16-MDCT scanners according to predefined imaging protocols. HR was measured with the patient in the supine position before and continuously for 5 minutes after contrast medium administration. Mean and peak increases in HR and the proportion of subjects with predefined HR increases (>5 to <10, 10 to <15, 15 to <20, >20 bpm) were compared in the 2 populations. Liver images were assessed by 2 independent, blinded readers for contrast enhancement [Hounsfield unit (HU)], using predefined regions-of-interest during the arterial and portal-venous phase of enhancement. RESULTS: Effects on HR: Eighty-four subjects received iopamidol-370 whereas 82 received iodixanol-320. Mean age, gender distribution, weight, total iodine dose, dose/body weight, concomitant medications and use of beta-blockers were comparable in the 2 groups. Mean baseline HR was similar in the 2 groups (iopamidol-370: 72.3 +/- 12.5 bpm; iodixanol-320: 74.5 +/- 11.9 bpm). Mean changes from baseline to peak postdose were similar in the 2 groups (8.0 +/- 9.3 bpm after iopamidol-370 and 8.4 +/- 14.7 after iodixanol-320, P = 0.72). The proportion of subjects in each group having increases of <5, >5 to <10, 10 to <15, 15 to <20, or >20 bpm was comparable (P = 0.87). Two subjects experienced postcontrast tachycardia (HR increase >70 bpm, peak HR of 146 and 164 bpm), both in the iodixanol-320 group (2.4%). Contrast Enhancement: Of the 121 patients undergoing liver CT, 60 received iopamidol-370 whereas 61 received iodixanol-320. Mean age, gender distribution, weight, total iodine dose, and dose/body weight were comparable in the 2 groups. Iopamidol-370 provided significantly higher HU values in abdominal aorta during the arterial phase of enhancement for both readers [R1: 301.3 +/- 80.2 vs. 273.6 +/- 65.9 HU, 95% confidence interval (6.1-56.8), P = 0.02; R2: 302.0 +/- 73.6 vs. 275.1 +/- 62.9 HU, 95% confidence interval (2.3-51.3), P = 0.03]. No significant difference was observed between the 2 contrast medium during the portal venous phase of enhancement. CONCLUSIONS: When the same injection rate and iodine dose is used, the effects on HR of bolus intravenous injections of iopamidol-370 and iodixanol-320 were similar. Iopamidol-370 provides significantly greater enhancement during the arterial phase and similar enhancement during the portal venous phase compared with iodixanol-320.

Duke Scholars

Published In

Invest Radiol

DOI

ISSN

0020-9996

Publication Date

December 2007

Volume

42

Issue

12

Start / End Page

856 / 861

Location

United States

Related Subject Headings

  • Triiodobenzoic Acids
  • Tomography, X-Ray Computed
  • Radiographic Image Enhancement
  • Prospective Studies
  • Nuclear Medicine & Medical Imaging
  • Male
  • Liver
  • Kidney Diseases
  • Kidney
  • Iopamidol
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sahani, D. V., Soulez, G., Chen, K.-M., Lepanto, L., Xu, J.-R., Nelson, R. C., … Investigators of the IMPACT Study, . (2007). A comparison of the efficacy and safety of iopamidol-370 and iodixanol-320 in patients undergoing multidetector-row computed tomography. Invest Radiol, 42(12), 856–861. https://doi.org/10.1097/RLI.0b013e3181514413
Sahani, Dushyant V., Gilles Soulez, Ke-Min Chen, Luigi Lepanto, Jian-Rong Xu, Rendon C. Nelson, Luigi Grazioli, Angelo Vanzulli, Jay P. Heiken, and Jay P. Investigators of the IMPACT Study. “A comparison of the efficacy and safety of iopamidol-370 and iodixanol-320 in patients undergoing multidetector-row computed tomography.Invest Radiol 42, no. 12 (December 2007): 856–61. https://doi.org/10.1097/RLI.0b013e3181514413.
Sahani DV, Soulez G, Chen K-M, Lepanto L, Xu J-R, Nelson RC, et al. A comparison of the efficacy and safety of iopamidol-370 and iodixanol-320 in patients undergoing multidetector-row computed tomography. Invest Radiol. 2007 Dec;42(12):856–61.
Sahani, Dushyant V., et al. “A comparison of the efficacy and safety of iopamidol-370 and iodixanol-320 in patients undergoing multidetector-row computed tomography.Invest Radiol, vol. 42, no. 12, Dec. 2007, pp. 856–61. Pubmed, doi:10.1097/RLI.0b013e3181514413.
Sahani DV, Soulez G, Chen K-M, Lepanto L, Xu J-R, Nelson RC, Grazioli L, Vanzulli A, Heiken JP, Investigators of the IMPACT Study. A comparison of the efficacy and safety of iopamidol-370 and iodixanol-320 in patients undergoing multidetector-row computed tomography. Invest Radiol. 2007 Dec;42(12):856–861.

Published In

Invest Radiol

DOI

ISSN

0020-9996

Publication Date

December 2007

Volume

42

Issue

12

Start / End Page

856 / 861

Location

United States

Related Subject Headings

  • Triiodobenzoic Acids
  • Tomography, X-Ray Computed
  • Radiographic Image Enhancement
  • Prospective Studies
  • Nuclear Medicine & Medical Imaging
  • Male
  • Liver
  • Kidney Diseases
  • Kidney
  • Iopamidol